Nonparametric response‐adaptive randomization for continuous responses.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 781, doi. 10.1002/pst.1900
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2018 AND VI 17 AND IP 6
Results: 17
1
2
Understanding the influence of individual variables contributing to multivariate outliers in assessments of data quality.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 846, doi. 10.1002/pst.1903
- By:
- Publication type:
- Article
3
A case study of an adaptive design for a clinical trial with 2 doses and 2 endpoints in a rare disease area.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 797, doi. 10.1002/pst.1902
- By:
- Publication type:
- Article
4
Reasonable two‐stage adaptive designs for single‐arm phase II clinical trials.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 770, doi. 10.1002/pst.1899
- By:
- Publication type:
- Article
5
Bayesian detection of potential risk using inference on blinded safety data.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 823, doi. 10.1002/pst.1898
- By:
- Publication type:
- Article
6
A practical guide to pre‐trial simulations for Bayesian adaptive trials using SAS and BUGS.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 854, doi. 10.1002/pst.1897
- By:
- Publication type:
- Article
7
Single arm two‐stage studies: Improved designs for molecularly targeted agents.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 761, doi. 10.1002/pst.1896
- By:
- Publication type:
- Article
8
A Bayesian hierarchal modeling approach to shortening phase I/II trials of anticancer drug combinations.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 750, doi. 10.1002/pst.1895
- By:
- Publication type:
- Article
9
Exact and asymptotic tests under the sequential parallel comparison design.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 835, doi. 10.1002/pst.1894
- By:
- Publication type:
- Article
10
Effect of a statistical outlier in potency bioassays.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 701, doi. 10.1002/pst.1893
- By:
- Publication type:
- Article
11
Phase 3 adaptive trial design options in treatment of complicated urinary tract infection.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 811, doi. 10.1002/pst.1892
- By:
- Publication type:
- Article
12
Subgroup‐specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 734, doi. 10.1002/pst.1891
- By:
- Publication type:
- Article
13
Bayesian dose‐finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 725, doi. 10.1002/pst.1890
- By:
- Publication type:
- Article
14
Points to consider for analyzing efficacy outcomes in long‐term extension clinical trials.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 685, doi. 10.1002/pst.1888
- By:
- Publication type:
- Article
15
A Bayesian K‐PD model for synergy: A case study.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 674, doi. 10.1002/pst.1887
- By:
- Publication type:
- Article
16
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 671, doi. 10.1002/pst.1829
- Publication type:
- Article
17
Uniformly most powerful Bayesian interval design for phase I dose‐finding trials.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 710, doi. 10.1002/pst.1889
- By:
- Publication type:
- Article